| 翻訳と辞書 |
| Ioflupane (123I) ： ウィキペディア英語版 |
Ioflupane (123I)
Ioflupane (123I) is the International Nonproprietary Name of a phenyltropane compound which is a neuro-imaging radiopharmaceutical drug, used by nuclear medicine physicians for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms. It is injected into a patient and viewed with a gamma camera in order to acquire SPECT images of the brain with particular respect to the striatum, a subcortical region of the basal ganglia.〔GE Healthcare Ltd. (DaTSCAN - Prescribing information )〕 The drug is sold under the tradename DaTSCAN and is manufactured by GE Healthcare, formerly Amersham plc. It is not marketed outside of Europe and the United States.
==Pharmacology==
DaTSCAN is a solution of ioflupane (123I) for injection into a living test subject.
The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera. I-123 has a half life of approximately 13 hours and a gamma photon energy of 159 keV making it an appropriate radionuclide for medical imaging. The solution also contains 5% ethanol to aid solubility and is supplied sterile since it is intended for intravenous use.
Ioflupane has a high binding affinity for presynaptic dopamine transporters (DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By introducing an agent that binds to the dopamine transporters a quantitative measure and spatial distribution of the transporters can be obtained.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Ioflupane (123I)」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|